LIMN 10-K & 10-Q changes, risk factors and insider trading
Liminatus Pharma, Inc. (also LIMNW) · Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 1971387 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare (only one so far)..
What changed in the latest 10-Q
Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
New heading “June 2026 Warrant Inducement”
New heading “InnocsAI Acquisition”
New heading “Comparison of the Six Months Ended June 30, 2026 and 2025”
New heading “Operating Expenses”
New heading “General and Administrative Expenses”
New heading “Research and Development Expenses”
New heading “Other (Expenses) Income, net”
Largest changes
“Pursuant to the Amended and Restated Merger Agreement, upon completion of the InnocsAI Merger, the members of InnocsAI would receive shares of our common stock up to the maximum number that could be issued without prior stockholder approval under applicable Nasdaq listing rules (or an estimated 19.99% of the outstanding common stock immediately prior to the closing of the InnocsAI Merger). …”see in full comparison
Full comparison: every changed paragraph (46)
Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the “Effective Time”), (i) every issued and outstanding security issued by Iris during its initial public offering (each, an “Iris Unit”) was automatically separated and broken out into its constituent parts and the holder thereof was deemed to hold one share of Iris Class A common stock, par value $0.0001 per share (the “Iris Class A Shares”) and one-fourth of one redeemable warrant that was included as part of each Iris Unit (the “Public Warrants”), and such underlying constituent securities of Iris were converted in accordance with the applicable terms of the Business Combination Agreement, (ii) at the Effective Time, each issued and outstanding Iris Class A Share was converted automatically into and thereafter represent the right to receive one share of common stock, par value $0.0001 per share (“Common Stock”),share, of the Company, following which all Iris Class A Shares ceased to be outstanding and were automatically canceled and ceased to exist, (iii) at the Effective Time, each issued and outstanding Public Warrant immediately and automatically represented the right to purchase shares of Commoncommon Stockstock on the same terms and conditions as are set forth in the applicable warrant agreement, (iv) at the Effective Time, each issued and outstanding non-redeemable warrant of Iris that was issued by Iris in a private placement at the time of the consummation of its initial public offering, entitling the holder thereof to purchase one Iris Class A Share at $11.50 per share, except those issued to Cantor Fitzgerald & Co. (“Cantor”), were forfeited, and (v) the private placement warrants issued to Cantor immediately and automatically represented the right to purchase shares of Commoncommon Stock.stock.
At the Closing Date, the Company issued an aggregate of 1,500,000 shares of the Company’s common stock in a private placement (the “PIPE Shares”) for the total consideration of $15,000,000 (the “PIPE Financing”). The PIPE Financing consisted of a cash and non - cash–non-cash component. Under the cash component, the Company received gross proceeds of $10,556,500, of which $7,129,500 came directly from the PIPE investor and $3,427,000 were funded indirectly by the PIPE investor, through promissory notes between Prophase Sciences, LLC, a related party of the Company, and Liminatus. At the Closing Date, the $3,427,000 in related party debts between Prophase Sciences, LLC and Liminatus was ultimately converted into shares as part of the PIPE Financing. As part of the PIPE Financing, the gross proceeds satisfied principal and accrued interest totaling $3,316,756, which was ultimately converted into shares as part of the PIPE Financing. The - non - cash component of the PIPE Financing included the conversion of $4,443,500 in amounts borrowed from a consortium of related parties. The $4,443,500 borrowed from the related parties were used to fund an unsecured promissory note between Liminatus and Iris. At the Closing Date, the unsecured promissory note was settled and the $4,443,500 in related party debts were ultimately converted into shares of the Company in a noncash transaction.
Upon the consummation of the Business Combination, the Iris Class A Shares, Iris Units and Public Warrants ceased trading on the OTC Pink Marketplace, and the CommonCompany’s Stockcommon stock and Public Warrants began trading on The Nasdaq Stock Market (“Nasdaq”) under the trading symbols “LIMN” and “LIMNW,” respectively.
On February 18, 2026, we closed a best efforts public offering for the sale of (i) 8,270,000 shares of our common stock, (ii) 5,543,000 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 5,543,000 shares of our common stock and (iii) 13,813,00020,719,500 common stock purchase warrants (the “Common Stock Warrants”) to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrant (the “Offering”), for aggregate net proceeds of approximately $3.44 million after deducting the estimated offering expenses, including the placement agent fees. Each pre-funded warrant has an exercise price of $0.0001 per share upon issuance for one share of common stock and will not expire prior to exercise. Each warrant has ana reduced exercise price of $0.29$0.18 per share, is exercisable upon issuance for one and a half shares of common stock,stock and will expire five years following the date of issuance. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Maxim Group LLC (“Maxim”) acted as the placement agent in connection with the Offering.
In connection with the Offering, on February 17, 2026, we entered into a placement agency agreement with Maxim Group LLC,Maxim, as placement agent in connection with the Offering (the “Placement Agent”).Offering. We paid the Placement AgentMaxim a cash fee of 8.0% of the aggregate gross proceeds raised in the Offering. We also agreed to reimburse the Placement AgentMaxim for all reasonable out-of-pocket costs and expenses incurred in connection with the Offering in an aggregate amount up to $100,000. In addition, we issued to the Placement AgentMaxim warrants (the “Placement Agent Warrants”) to purchase 690,650 shares of common stock (representing 5.0% of the number of shares of common stock sold in the Offering). The Placement Agent Warrants are immediately exercisable at an exercise price of $0.319 (or 110% of the public offering price for the shares of common stock and common warrants offered in the Offering) and will expire on the fifth anniversary of the commencement of sales of the Offering.
June 2026 Warrant Inducement
On June 3, 2026, we entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder of our existing common stock warrants exercisable for an aggregate of 10,344,000 shares of our common stock (collectively, the “Existing Warrants”), to exercise its Existing Warrants at a reduced exercise price of $0.18 per share, in exchange for our agreement to issue new common stock warrants to purchase an aggregate of up to 20,688,000 shares of common stock, consisting of (i) warrants to purchase up to 10,344,000 shares of common stock at an exercise price per share of $0.18 (the “New Black-Scholes Warrants”) and (ii) warrants to purchase up to 10,344,000 shares of common stock at an exercise price per share of $0.18 (the “New Change of Control Warrants” and, together with the New Black-Scholes Warrants, the “Inducement Warrants”) (the “Warrant Inducement”). The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $1,861,921, before deducting financial advisory fees. The fair value of the Inducement Warrants was $2,211,295 at inducement, or $0.18 per instrument.
In connection with the transaction described above, we entered into a financial advisory services agreement, dated June 3, 2026, with Maxim, pursuant to which we agreed to pay Maxim for its services a cash fee of up to 8% of the gross proceeds received by us in connection with the exercise of the Existing Warrants.
The Warrant Inducement, which resulted in the issuance of the Company’s common stock in exchange for the cash exercise of the Existing Warrants, is considered a modification of the Existing Warrants under the guidance of ASC 815-40. The modification is consistent with the “Equity Issuance” classification under that guidance as the reason for the modification was to induce the holders of the Existing Warrants to cash exercise their warrants, resulting in the imminent exercise of the Existing Warrants, which raised equity capital and generated net proceeds for the Company. As the Existing Warrants were classified as equity instruments before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of $117,806 as an equity issuance cost. The amount of the equity issuance cost recognized for the warrant modification was determined at the incremental fair value of the modified Existing Warrants immediately before and after the warrant modification.
InnocsAI Acquisition
On May 17, 2026, we entered into a Merger Agreement (the “Original Merger Agreement”) with InnocsAI LLC, a Delaware limited liability company (“InnocsAI”), and NamChul Jung, in his capacity as the representative of the members of InnocsAI. Under the Original Merger Agreement, the aggregate consideration payable to the members of InnocsAI consisted of (i) 1,600,000,000 shares of our common stock, valued at an issuance price of $0.20 per share (the “Closing Payment Shares”), and (ii) contingent value rights, on terms to be agreed upon by the parties, representing in the aggregate the right to receive 20% of the net proceeds from any future strategic sale, out-license, transfer or other disposition of, or exit transaction involving, the assets acquired from InnocsAI. Upon completion of the transactions contemplated by the Original Merger Agreement, all issued and outstanding membership interests of InnocsAI were to be canceled and automatically converted into the right to receive the Closing Payment Shares.
The assets to be acquired included a portfolio of oncology-focused biologic and cellular therapy programs centered on CAR-T and antibody-related technologies. These technologies are designed to address certain limitations observed in current approaches to hematologic malignancies and solid tumors, including antigen escape, tumor heterogeneity, limited T-cell persistence, tumor microenvironment-mediated suppression and lineage-restricted target coverage. Chris Kim, our Chief Executive Officer and a member of our board of directors, is also a director of InnocsAI and the Chief Executive Officer and controlling member of Valetudo Therapeutics LLC, a member of InnocsAI.
On June 29, 2026, we, InnocsAI and Mr. Jung amended and restated the Original Merger Agreement (as so amended and restated, the “Amended and Restated Merger Agreement”). The Amended and Restated Merger Agreement revised the structure of the transaction to allow closing prior to obtaining stockholder approval and provided that the 1,600,000,000 shares of our common stock comprising the merger consideration would instead be paid in a combination of shares of common stock and shares of newly designated non-voting convertible preferred stock. As contemplated by the Original Merger Agreement, and subject to the terms and conditions of the Amended and Restated Merger Agreement, InnocsAI would merge with and into a new wholly-owned Delaware subsidiary (“Merger Sub”), with InnocsAI ceasing to exist as a separate legal entity and Merger Sub continuing as the surviving entity (the “InnocsAI Merger”).
Pursuant to the Amended and Restated Merger Agreement, upon completion of the InnocsAI Merger, the members of InnocsAI would receive shares of our common stock up to the maximum number that could be issued without prior stockholder approval under applicable Nasdaq listing rules (or an estimated 19.99% of the outstanding common stock immediately prior to the closing of the InnocsAI Merger). The balance of the merger consideration would be paid in shares of our newly designated Series A Non-Voting Convertible Preferred Stock (the “Series A Preferred Stock”), having the rights, preferences, powers and privileges set forth in the applicable Certificate of Designation (as defined below). Each share of Series A Preferred Stock would be convertible into 10,000 shares of common stock. The Series A Preferred Stock would not become convertible unless and until we obtained stockholder approval for the issuance of the underlying shares of common stock to the extent required under applicable Nasdaq listing rules.
On July 2, 2026, the InnocsAI Merger was completed, pursuant to which we acquired InnocsAI. In connection with the closing of the InnocsAI Merger, we issued to the former members of InnocsAI an aggregate of 11,188,729 shares of common stock and an aggregate of 158,881.1271 shares of Series A Preferred Stock.
Pursuant to the Amended and Restated Merger Agreement, we acquired InnocsAI which is primarily composed of intangible assets (i.e. its portfolio of oncology-focused biologic and cellular therapy program). The InnocsAI Merger is further considered an asset acquisition under ASC 805 as it does not meet the definition of a business since substantially all of the fair value of the assets acquired are concentrated in a group of similarly identifiable assets. Furthermore, the InnocsAI Merger was deemed to be an asset acquisition as InnocsAI did not meet the definition of a business under SEC Rule 11-01 (d) of Regulation S-X (“Rule 11-01 (d)”), where a business, for purposes of Rule 11-01 (d), is identified by the continuity of operations before and after the transaction. InnocsAI has no substantive revenue producing activities, employee base, sales force, customer base, operating rights or production techniques, thus, not meeting the definition of a business under Rule 3-05.
On June 29, 2026, in connection with the Amended and Restated Merger Agreement, we entered into a registration rights agreement (the “Registration Rights Agreement”) with the existing members of InnocsAI, pursuant to which we have agreed to provide such holders with “piggy-back” and Form S-3 registration rights, covering shares of common stock (including shares issuable upon conversion of preferred stock) received in the InnocsAI Merger. We have agreed to bear the registration expenses.
On June 29, 2026, in connection with the Amended and Restated Merger Agreement, InnocsAI, for the benefit of the Company and its affiliates, successors and subsidiaries, entered into a non-competition and non-solicitation agreement (the “Non-Compete Agreement”) with certain key employees of InnocsAI, pursuant to which each subject party has agreed not to compete with or solicit the employees, customers, or suppliers of InnocsAI and its affiliates for two years after the merger closing, and to maintain confidentiality regarding company information.
Comparison of the Three Months Ended MarchJune 31,30, 2026 and 2025
The following is a comparative of our results of operations for the three months ended MarchJune 31,30, 2026 and 2025:
General and administrative expenses consists primarily of professional service fees, including accounting and legal services and other general operating expenses. General and administrative expenses increaseddecreased by $436,678$339,303 during the three months ended MarchJune 31,30, 20262026, as compared to the three months ended MarchJune 31,30, 20252025, primarily due to increases in accounting and legal expenses incurred in connection with the CompanyBusiness nowCombination operatingduring the three months ended June 30, 2025, as publiclycompared tradedto company.no such costs during the three months ended June 30, 2026.
Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (“Innobation”) who wasis performing the research and development activities for the Company in accordance with the license agreements with Innobation. Research and development expenses increased by $400,000$600,000 as a result of costs incurred under the CD47 license agreement during the three months ended MarchJune 31,30, 2026 as compared no such costs incurring during the three months ended MarchJune 31,30, 2025.
Other Expenses,(Expenses) Income, net
The other (expense) income, net decreased by $1,259,849 from $1,231,498 of other income for the three months ended June 30, 2025 to $28,351 of other expense for the three months ended June 30, 2026. The decrease in other (expenses) income, net is primarily due to a decrease in amounts of unrelated vendor payables forgiven of $2,130,782. Furthermore, the Company recognized an unrealized loss on the change in the fair value of deferred underwriting fee common stock payable of $756,000 during the three months ended June 30, 2025 as compared to no such loss during the three months ended June 30, 2026.
Comparison of the Six Months Ended June 30, 2026 and 2025
The following is a comparative of our results of operations for the six months ended June 30, 2026 and 2025:
Operating Expenses
General and Administrative Expenses
General and administrative expenses consists primarily of professional service fees, including accounting and legal services and other general operating expenses. General and administrative expenses increased by $97,375 during the six months ended June 30, 2026 as compared to the six months ended June 30, 2025 primarily due to higher accounting and legal expenses incurred as a result of the Company operating as a publicly traded company following the closing of the Business Combination, whereas the Company was not publicly traded prior to the Business Combination.
Research and Development Expenses
Research and development expenses consist of costs incurred by Innobation who is performing the research and development activities for the Company in accordance with the license agreements with Innobation. Research and development expenses increased by $1,000,000 as a result of costs incurred under the CD47 license agreement during the six months ended June 30, 2026 as compared to no such costs incurring during the six months ended June 30, 2025.
Other (Expenses) Income, net
The other (expense) income, net decreased by $1,219,359 from $1,168,192 of other income for the six months ended June 30, 2025 to $51,167 of other expense for the six months ended June 30, 2026. The decrease in other (expenses) income, net is primarily due to a decrease in amounts of unrelated vendor payables forgiven of $2,130,782 during the six months ended June 30, 2026 as compared to the six months ended June 30, 2025. Furthermore, the Company recognized an unrealized loss on the change in the fair value of deferred underwriting fee common stock payable of $756,000 during the six months ended June 30, 2025 as compared to no such loss during the six months ended June 30, 2026.
The other expense, net decreased by $40,490 from $63,306 of other expense for the three months ended March 31, 2025 to $22,816 of other expense for the three months ended March 31, 2026. The Company recognized interest expense of $18,638 on related party promissory notes during the three months ended March 31, 2026 as compared to interest expense of $115,512 during the three months ended March 31, 2025 due to a decrease in the related party promissory notes principal balance following the closing of the Business Combination. Further, the Company recognized no interest income on loans receivable with Iris during the three months ended March 31, 2026 as compared to interest income of $52,206 during the three months ended March 31, 2025. In connection with the closing of the Business Combination on April 30, 2025, the loans receivable with Iris were terminated, thus no interest income is expected in future periods.
The Company is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for one year after the date that the condensed consolidated financial statements are issued. Through MarchJune 31,30, 2026, the Company has funded its operations mainly through equity and debt financings, including the proceeds from the Mergers andMergers, the PIPE Financing, the Offering and the OfferingWarrant (as described below).Inducement.
As of MarchJune 31,30, 2026, the Company had $1,907,674$3,017,096 of cash in its bank accounts. As of MarchJune 31,30, 2026 and December 31, 2025,2026, there was $1,442,500 of related party debts, which are included in Short-termshort-term debt, related parties in the accompanying unaudited condensed consolidated balance sheets.sheets (see Note 4).
The Company has an accumulated deficit of $39,995,447$41,402,706 as of MarchJune 31,30, 2026. The Company had a loss from operations and net loss of $1,100,898$2,479,806 and $1,123,714,$2,530,973, respectively, for the threesix months ended MarchJune 31,30, 2026. The Company had a loss from operations and net loss of $264,220$1,378,908 and $327,526,$1,407,259, respectively, for the three months ended MarchJune 31,30, 2025.2026.
On February 18, 2026, the Company completed a “best efforts” public offering of (i) 8,270,000 shares of its common stock, (ii) 5,543,000 pre-fundedPre-Funded warrantsWarrants to purchase up to 5,543,000 shares of common stock (the “Pre-Funded Warrants”) and (ii) 13,813,00020,719,500 commonCommon stockStock purchase warrantsWarrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per Pre-Funded Warrant) and accompanying warrant (the “Offering”).warrant. In connection with the Offering, the Company received net proceeds of approximately $3.44 million,$3,444,427, after deducting the estimated offering expenses payable by the Company, including the placement agent fees.
On June 3, 2026, the Company entered into the Inducement Letter Agreement with a holder of its Existing Warrants to exercise 10,344,000 of its Existing Warrants at a reduced exercise price of $0.18 per share for an aggregate of 10,344,000 shares of its common stock. In connection with the Warrant Inducement, the Company received net proceeds of $1,622,967, after deducting the estimated offering expenses payable by the Company including the placement agent fees.
Management’s plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations. There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all. The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.
The following table summarizes our cash flows for the threesix months ended MarchJune 31,30, 2026 and 2025:
Net cash used in operating activities for the six months ended June 30, 2026 decreased by $5,990,571 as compared to the six months ended June 30, 2025. The decrease in cash used in operating activities is primarily due to decreases in due from related parties of $3,427,000, a decrease in amounts of unrelated vendor payables forgiven of $2,142,297, payment of accounts payable and accrued expenses of $1,812,806 and amounts due to research and development partner of $1,782,297 offset by an increase in net loss of $2,391,734 and increase in the fair value of deferred underwriting fees of common stock payable of $756,000, for the six months ended June 30, 2026 as compared to the same period in the prior year.
Net cash used in operating activities for the three months ended March 31, 2026 increased by $1,855,896 as compared to the three months ended March 31, 2025. The increase in cash used in operating activities is primarily due to an increase in net loss during the three months ended March 31, 2026 of $935,688, when compared to the net loss for the three months ended March 31, 2025, an increase in prepaid expenses of $657,107 and an increase in payment of accounts payable and accrued expenses of $173,923 for the three months ended March 31, 2026 as compared to the same period in the prior year. The increasedecrease is further a result of operating activities, adjusted for non-cash transactions including deprecation expenseforgiveness of $518unrelated andvendor apayables of $2,142,297 offset by the change in the fair value of warrantdeferred liabilitiesunderwriting fees of $4,178common stock payable of $756,000 for the threesix months ended MarchJune 31,30, 2026 as compared to no such activity during the threesix months ended MarchJune 31,30, 2025 Net cash used in investing activities for the threesix months ended MarchJune 31,30, 2026 decreased by $575,000$775,000 as compared to the threesix months ended MarchJune 31,30, 2025. The decrease in cash used in investing activities is primarily due to less issuances of loans to Iris priordue to the completion of the Business Combination.
Net cash provided by financing activities for the threesix months ended MarchJune 31,30, 2026 increaseddecreased by $2,872,308$5,368,033 as compared to the threesix months ended MarchJune 31,30, 2025. The increasedecrease in cash provided by financing activities is primarily due to gross proceeds received of $3,585,308$10,556,500, offset by $2,563,738 in payments for transaction costs in connection with the Business Combination during the six months ended June 30, 2025 as compared to the aggregate gross proceeds of $5,664,729 received from the Offering, netthe Warrant Inducement and the exercise of offeringwarrants costs.during the six months ended June 30, 2026. Further, the Company received nohad proceeds from related party debt of $4,340,000, which is offset by payments of related party debt of $1,300,000 during the threesix months ended MarchJune 31,30, 20262025. asNo comparedsuch topayments proceeds of $713,000occurred during the threesix months ended MarchJune 31,30, 2025.2026.
The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing liabilities from equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance, modification, and as of each subsequent quarterly period end date while the warrants are outstanding. As of MarchJune 31,30, 2026, 13,813,00020,688,000 ofInducement theWarrants, Company’s9,625,500 Common Stock Warrants, 690,650 Placement Agent Warrants and 5,094,623 of the Company’s Public Warrants were accounted for as equity-classified instruments and 835,555 private placement warrants were accounted for as liability-classified instruments.
For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the liability-classified warrants are recognized as a non-cash gain or loss on the accompanying consolidated statements of operations and comprehensive loss. The Company assesses the classification of its warrants at each reporting date to determine whether a change in classification between equity and liability is required. During the three and six months ended MarchJune 31,30, 2026, the Company had an unrealized gain on the change in fair value of the warrant liabilities of $4,178.$29,245 and $33,423, respectively. During the three and six months ended MarchJune 31,30, 2025, the Company had noan unrealized gain or loss on the change in fair value of the warrant liabilities.liabilities of $116,894.
LIMN insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Valetudo Therapeutics Llc |
Other | 3,448,926 | — | — |
| 2026-06-24 | Valetudo Therapeutics Llc |
Other | 4,373,603 | — | — |
Well-known investors holding LIMN (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| Citadel Advisors (Ken Griffin) | 2026-06-30 | 56,089 | $6.2K | 0.0% | Reduced 92% |
| D. E. Shaw & Co. | 2026-06-30 | 83,353 | $2.9K | 0.0% | No change |